Page 22 Bain Capital Helthcare
P. 22
Psychosis
Affect
Cognition
Motor Function
Epileptiform Activity
Mood Disorders
Officer. “We had great molecules
that could eventually become new
medicines. We were able to attract
some of the best talent to take care
of these assets and deliver them to
patients to really help them and to
have their lives improve.”
“We didn’t have a name, we didn’t have
office space,” remembers Will Cozean,
a Managing Director on Bain Capital’s
Life Sciences team. “We had 11 clinical
and preclinical programs and the right
to develop them. We brought in people
from our Portfolio Group to help build a
new business infrastructure. Not many
firms can tackle something like that.”
The firm’s Portfolio Group is a key
contributor in many investments. In
the case of Cerevel, they worked with
the investment team to rapidly create
the infrastructure to support a world-
class biopharmaceutical business. This
included securing appropriate space,
installing IT and finance systems, and
recruiting leaders for key roles in clinical
development, science, finance, and
human resources—what Coles refers
to as “the best, A+ talent that’s in the
industry.”
With those pieces in place, Bain Capital
Life Sciences, our partners at Pfizer,
and the Cerevel team focused on
advancing the pipeline.
From Concept to Reality
Cerevel compounds have made
important progress. Since going public
in 2020, Cerevel has shown exciting
data in both multiple therapeutic areas.
This momentum enabled Cerevel
to raise over $2B in capital since
inception.
“Great businesses are built because of
great teams,” notes Adam Koppel, a
Partner with Bain Capital Life Sciences.
“Bain Capital is uniquely positioned
to partner with the biopharmaceutical
industry because of our deep content
knowledge, our business building
experience, our balance sheet and,
most importantly, our culture of
partnership, which creates the most
value for investors—and for patients.”
After an amazing five-year plus journey,
in August 2024 AbbVie acquired
Cerevel for $8.7B.
DISCOVERY AND DEVELOPMENT
Selectively targeting the receptor subtype related to
disease physiology
M4
• Schizophrenia
• Dementia-Related
Psychosis in
Alzheimer’s and
Parkinson’s Diseases
GABA
A
• Epilepsy
GABA
A
• Panic Disorder
PDE4B
• Major Depressive Disorder
• Schizophrenia
D1/D5
• Parkinson’s Disease
KOR
• Major Depressive Disorder
• Bipolar Depression
D1/D5
• Dementia-Related Apathy
22
Bain Capital
Healthcare
Affect
Cognition
Motor Function
Epileptiform Activity
Mood Disorders
Officer. “We had great molecules
that could eventually become new
medicines. We were able to attract
some of the best talent to take care
of these assets and deliver them to
patients to really help them and to
have their lives improve.”
“We didn’t have a name, we didn’t have
office space,” remembers Will Cozean,
a Managing Director on Bain Capital’s
Life Sciences team. “We had 11 clinical
and preclinical programs and the right
to develop them. We brought in people
from our Portfolio Group to help build a
new business infrastructure. Not many
firms can tackle something like that.”
The firm’s Portfolio Group is a key
contributor in many investments. In
the case of Cerevel, they worked with
the investment team to rapidly create
the infrastructure to support a world-
class biopharmaceutical business. This
included securing appropriate space,
installing IT and finance systems, and
recruiting leaders for key roles in clinical
development, science, finance, and
human resources—what Coles refers
to as “the best, A+ talent that’s in the
industry.”
With those pieces in place, Bain Capital
Life Sciences, our partners at Pfizer,
and the Cerevel team focused on
advancing the pipeline.
From Concept to Reality
Cerevel compounds have made
important progress. Since going public
in 2020, Cerevel has shown exciting
data in both multiple therapeutic areas.
This momentum enabled Cerevel
to raise over $2B in capital since
inception.
“Great businesses are built because of
great teams,” notes Adam Koppel, a
Partner with Bain Capital Life Sciences.
“Bain Capital is uniquely positioned
to partner with the biopharmaceutical
industry because of our deep content
knowledge, our business building
experience, our balance sheet and,
most importantly, our culture of
partnership, which creates the most
value for investors—and for patients.”
After an amazing five-year plus journey,
in August 2024 AbbVie acquired
Cerevel for $8.7B.
DISCOVERY AND DEVELOPMENT
Selectively targeting the receptor subtype related to
disease physiology
M4
• Schizophrenia
• Dementia-Related
Psychosis in
Alzheimer’s and
Parkinson’s Diseases
GABA
A
• Epilepsy
GABA
A
• Panic Disorder
PDE4B
• Major Depressive Disorder
• Schizophrenia
D1/D5
• Parkinson’s Disease
KOR
• Major Depressive Disorder
• Bipolar Depression
D1/D5
• Dementia-Related Apathy
22
Bain Capital
Healthcare
